<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00718029</url>
  </required_header>
  <id_info>
    <org_study_id>MK: 33132</org_study_id>
    <nct_id>NCT00718029</nct_id>
  </id_info>
  <brief_title>Cerebrospinal Fluid (CSF) Raltegravir Substudy</brief_title>
  <official_title>MK: Raltegravir Concentrations in Cerebrospinal Fluid</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Diego</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Diego</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to measure concentrations of Raltegravir in cerebrospinal fluid.

      The hypotheses are:

        -  Raltegravir concentrations in CSF will be measurable

        -  Raltegravir concentrations in CSF will remain constant, while plasma concentrations vary
           widely leading to highly variable CSF-to-plasma ratios.

        -  Following at least 4 weeks of Raltegravir-containing combination therapy, HIV RNA levels
           in CSF will be below 50 copies/mL in all subjects.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Enrolling by invitation</last_known_status>
  <start_date>July 2008</start_date>
  <primary_completion_date type="Anticipated">July 2009</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment type="Anticipated">15</enrollment>
  <condition>HIV Infections</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      CSF, PBMC, plasma
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Participants will be selected from participants already enrolled in Merck-sponsored
        Raltegravir Clinical Trials.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Enrollment in a raltegravir parent protocol at UCSD.

          -  Willing to undergo lumbar puncture.

          -  Able to give informed consent. If cognitively impaired, a test will be administered to
             ensure adequate comprehension of the consent document and procedure.

        Exclusion Criteria:

          -  Relative or absolute contraindication to lumbar puncture, such as current
             coagulopathy, thrombocytopenia (platelets&lt;50,000/ÂµL), hemophilia, or use of
             anticoagulant medication.

          -  Psychiatric disease that would interfere with study participation, in the opinion of
             the investigator.

          -  No major opportunistic infections within 30 days.

          -  Moderate or severe cognitive impairment. The proposed study does not have a
             neuropsychological objective.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Scott L Letendre, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Diego AntiViral Research Center</affiliation>
  </overall_official>
  <verification_date>July 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 16, 2008</study_first_submitted>
  <study_first_submitted_qc>July 17, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 18, 2008</study_first_posted>
  <last_update_submitted>July 23, 2008</last_update_submitted>
  <last_update_submitted_qc>July 23, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 24, 2008</last_update_posted>
  <responsible_party>
    <name_title>Scott Letendre, MD</name_title>
    <organization>UCSD AVRC</organization>
  </responsible_party>
  <keyword>Human Immunodeficiency Virus</keyword>
  <keyword>Cerebrospinal Fluid</keyword>
  <keyword>Raltegravir</keyword>
  <keyword>Drug Concentrations</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Raltegravir Potassium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

